These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 33843044)

  • 1. An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis.
    Wasiak M; Tajstra M; Kosior D; Gąsior M
    Cardiol J; 2023; 30(1):117-124. PubMed ID: 33843044
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials.
    Wolff G; Lin Y; Karathanos A; Brockmeyer M; Wolters S; Nowak B; Fürnkranz A; Makimoto H; Kelm M; Schulze V
    Clin Res Cardiol; 2017 Jul; 106(7):501-513. PubMed ID: 28213711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
    El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis.
    Siddiqui WJ; Aggarwal S; Rafique M; Singh S; Kutalek S; Eisen HJ
    Heart Fail Rev; 2018 Mar; 23(2):181-190. PubMed ID: 29380177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis.
    Kolodziejczak M; Andreotti F; Kowalewski M; Buffon A; Ciccone MM; Parati G; Scicchitano P; Uminska JM; De Servi S; Bliden KP; Kubica J; Bortone A; Crea F; Gurbel P; Navarese EP
    Ann Intern Med; 2017 Jul; 167(2):103-111. PubMed ID: 28632280
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.
    Romero J; Chaudhary R; Garg J; Lupercio F; Shah N; Gupta R; Nazir T; Bozorgnia B; Natale A; Di Biase L
    J Interv Card Electrophysiol; 2017 Sep; 49(3):263-270. PubMed ID: 28674918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients.
    Lee JH; Yu HT; Oh IY; Choi EK; Sung JH; Lee YS; Kim JY; Baek Y; Park J; Joung B;
    Yonsei Med J; 2020 Nov; 61(11):942-950. PubMed ID: 33107237
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials.
    Barakat AF; Saad M; Elgendy AY; Mentias A; Abuzaid A; Mahmoud AN; Elgendy IY
    BMJ Open; 2017 Jun; 7(6):e016352. PubMed ID: 28637742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Luni FK; Singh H; Khan AR; Malik SA; Khawaja O; Riaz H; Lee W; Kabour A; Richards M; Aasbo J
    J Cardiovasc Electrophysiol; 2017 May; 28(5):538-543. PubMed ID: 28370885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Primary Prevention Implantable Cardioverter Defibrillators in Patients With Nonischemic Cardiomyopathy: A Meta-analysis.
    Al-Khatib SM; Fonarow GC; Joglar JA; Inoue LYT; Mark DB; Lee KL; Kadish A; Bardy G; Sanders GD
    JAMA Cardiol; 2017 Jun; 2(6):685-688. PubMed ID: 28355432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The mortality for the implantable cardiac defibrillator in nonischemic cardiomyopathy: An updated systematic review and meta-analysis.
    He W; Xue C; Zheng J; Shuai Z
    Clin Cardiol; 2022 Dec; 45(12):1163-1170. PubMed ID: 36056632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
    Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A
    Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials.
    Hess PL; Al-Khatib SM; Han JY; Edwards R; Bardy GH; Bigger JT; Buxton A; Cappato R; Dorian P; Hallstrom A; Kadish AH; Kudenchuk PJ; Lee KL; Mark DB; Moss AJ; Steinman R; Inoue LY; Sanders G
    Circ Cardiovasc Qual Outcomes; 2015 Mar; 8(2):179-86. PubMed ID: 25669833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter defibrillators for primary prevention in patients with ischemic and non-ischemic cardiomyopathy: A meta-analysis.
    Jaiswal V; Taha AM; Joshi A; Deb N; Kanagala SG; Nebuwa C; Ang SP; Halder A; Rajak K; Jha M; Pallath Harshakumar S; Mattumpuram J
    Curr Probl Cardiol; 2024 Feb; 49(2):102198. PubMed ID: 37952790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Implantable cardioverter-defibrillators in heart failure patients with reduced ejection fraction and diabetes.
    Sharma A; Al-Khatib SM; Ezekowitz JA; Cooper LB; Fordyce CB; Michael Felker G; Bardy GH; Poole JE; Thomas Bigger J; Buxton AE; Moss AJ; Friedman DJ; Lee KL; Steinman R; Dorian P; Cappato R; Kadish AH; Kudenchuk PJ; Mark DB; Peterson ED; Inoue LYT; Sanders GD
    Eur J Heart Fail; 2018 Jun; 20(6):1031-1038. PubMed ID: 29761861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic implantation of cardioverter defibrillators in idiopathic nonischemic cardiomyopathy for the primary prevention of death: a narrative review.
    Cevik C; Nugent K; Perez-Verdia A; Fish RD
    Clin Cardiol; 2010 May; 33(5):254-60. PubMed ID: 20513063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit: Insights From the DANISH Trial.
    Kristensen SL; Levy WC; Shadman R; Nielsen JC; Haarbo J; Videbæk L; Bruun NE; Eiskjær H; Wiggers H; Brandes A; Thøgersen AM; Hassager C; Svendsen JH; Høfsten DE; Torp-Pedersen C; Pehrson S; Signorovitch J; Køber L; Thune JJ
    JACC Heart Fail; 2019 Aug; 7(8):717-724. PubMed ID: 31302052
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.